Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene

Stem Cells

Volumn 27, Issue 11, 2009, Pages 2815-2823

  Leuci, Valeria ^a   Gammaitoni, Loretta ^a   Capellero, Sonia ^a   Sangiolo, Dario ^a   Mesuraca, Maria ^b   Bond, Heather M ^b   Migliardi, Giorgia ^a   Cammarata, Cristina ^a   Aglietta, Massimo ^a   Morrone, Giovanni ^b   Piacibello, Wanda ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Gene therapy; Hematopoietic stem cells; Lentiviral vectors; Promoters

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; UBIQUITIN C; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL; CD34 SELECTION; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ENHANCER REGION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PERFORMANCE; PRODUCTIVITY; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY SEQUENCE; RESEARCH; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; TRANSGENE; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; CELL LINEAGE; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; LENTIVIRUS; MICE; MICE, INBRED NOD; MICE, SCID; POLYMERASE CHAIN REACTION; REGULATORY ELEMENTS, TRANSCRIPTIONAL; T-LYMPHOCYTES; WISKOTT-ALDRICH SYNDROME PROTEIN;

MUS;

EID: 72849119069     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.224     Document Type: Article

References (27)

1. Gaspar HB, Parsley KL, Howe S et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviralvector. Lancet 2004;364:2181-2187. (Pubitemid 40018447)
2. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 Or SETBP1. Nat Med 2006;12:401-409.
3. Aiuti A, Slavin S, Aker M et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413. (Pubitemid 34734219)
4. Williams DA, Nienhuis AW, Hawley RG et al. Gene Therapy 2000. Hematology Am Soc Hematol Educ Program. 2000:376-393.
5. Sirven A, Ravet E, Charneau P et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 2001;3:438-448. (Pubitemid 32509837)
6. Parolini O, Berardelli S, Riedl E et al. Expression of Wiskott-Aldrich syndrome protein (WASP) gene during hematopoietic differentiation. Blood 1997;90:70-75. (Pubitemid 27276549)
7. Petrella A, Doti I, Agosti V et al. A 5′ regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. Blood 1998;91:4554-4560. (Pubitemid 28270303)
8. Piacibello W, Sanavio F, Severino A et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: Evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999;93:3736-3749. (Pubitemid 29249820)
9. Lois C, Hong EJ, Pease S et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-872. (Pubitemid 34118370)
10. Piacibello W, Bruno S, Sanavio F et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood 2002;100:4391-4400. (Pubitemid 35429677)
11. Piacibello W, Sanavio F, Garetto L et al. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. Leukemia 1998;12:718-727. (Pubitemid 28220825)
12. Almarza E, Rio P, Meza NW et al. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. Mol Ther 2007;15:1487-1494. (Pubitemid 47099306)
13. Baum C, Kustikova O, Modlich U et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Human Gene Therapy 2006;17:253-263.
14. Montini E, Cesana D, Schmidt M et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696. (Pubitemid 43882120)
15. Kustikova O, Fehse B, Modlich U et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005;308:1171-1174. (Pubitemid 40696434)
16. Dupré L, Trifari S, Follenzi A et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther 2004;10:903-915. (Pubitemid 39419917)
17. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-256. (Pubitemid 36077924)
18. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
19. Hagemann TL, Kwan SP. The identification and characterization of two promoters and the complete genomic sequence for the Wiskott-Aldrich syndrome gene. Biochem Biophys Res Commun 1999;256:104-109.
20. Li Z, Dullmann J, Schiedlmeier B et al. Murine leukemia induced by retroviral gene marking. Science 2002;296:497. (Pubitemid 34408663)
21. Martín F, Toscano MG, Blundell M et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005;12:715-723. (Pubitemid 40561509)
22. Modlich U, Kustikova OS, Schmidt M et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005;105:4235-4246.
23. Seggewiss R, Pittaluga S, Adler RL et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006;107:3865-3867. (Pubitemid 43726789)
24. Charrier S, Dupre L, Scaramuzza S et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007;14:415-428. (Pubitemid 46306542)
25. Dupré L, Marangoni F, Scaramuzza S et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Human Gene Ther 2006;17:303-313.
26. Frecha C, Toscano MG, Costa C et al. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther 2008;15:930-941. (Pubitemid 351791480)
27. Weber EL, Cannon PM. Promoter choice for retroviral vectors: Transcriptional strength versus trans-activation potential. Human Gene Ther 2007;18:849-860.